Evidence map›Paper›PMID 26738536›Full record

ArticleBlood2016

Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.

Andreas Willerslev-Olsen, Thorbjørn Krejsgaard, Lise M Lindahl, Ivan V Litvinov, Simon Fredholm, David L Petersen, Claudia Nastasi, Robert Gniadecki, Nigel P Mongan, Denis Sasseville and 8 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07781449 (An Investigator-Initiated, Descriptive, Proof-of-Concept, Open-Label Pilot Study Focusing on Topical JAK Inhibition as a Novel Treatment of Cutaneous T-Cell Lymphoma), which is not on this map. Cited by 56 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07781449 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

An Investigator-Initiated, Descriptive, Proof-of-Concept, Open-Label Pilot Study Focusing on Topical JAK Inhibition as a Novel Treatment of Cutaneous T-Cell Lymphoma

TypeinterventionalSponsorAarhus University HospitalRan2026 to 2030Enrolled15ConditionsMycosis Fungoides, Cutaneous T-cell LymphomaArmsdelgocitinib
3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Immune interplay between sepsis and haematological malignancies.Intensive care medicine experimental · 2026
    Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Role of Antigenic Stimulation in Cutaneous T-Cell Lymphomas.The Journal of investigative dermatology · 2024
    Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. miRNA Signature in Early-stage Mycosis Fungoides.Acta dermato-venereologica · 2022
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 4 countries.

Andreas Willerslev-OlsenDepartment of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark;
Thorbjørn KrejsgaardDepartment of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark;
Lise M LindahlDepartment of Dermatology, Aarhus University Hospital, Skejby, Aarhus, Denmark;
Ivan V LitvinovDivision of Dermatology, University of Ottawa, Ottawa, ON, Canada;
Simon FredholmDepartment of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark;
David L PetersenDepartment of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark;
Claudia NastasiDepartment of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark;
Robert GniadeckiDepartment of Dermatology, Copenhagen University Hospital, Bispebjerg, Copenhagen, Denmark;
Nigel P MonganFaculty of Medicine and Health Science, School of Veterinary Medicine and Science, University of Nottingham, Loughborough, United Kingdom;
Denis SassevilleDivision of Dermatology, McGill University Health Centre, Montréal, QC, Canada;
Mariusz A WasikDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA;
Charlotte M BonefeldDepartment of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark;
Carsten GeislerDepartment of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark;
Anders WoetmannDepartment of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark;
Lars IversenDepartment of Dermatology, Aarhus University Hospital, Skejby, Aarhus, Denmark;
Mogens KilianDepartment of Biomedicine, Aarhus University, Aarhus, Denmark; and.
Sergei B KoralovDepartment of Pathology, New York University School of Medicine, New York, NY.
Niels OdumDepartment of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark;
University of Copenhagen · DKAarhus University Hospital · DKAarhus University · DKCopenhagen University Hospital · DKMcGill University Health Centre · CANew York University · USUniversity of Nottingham · GBUniversity of Ottawa · CAUniversity of Pennsylvania · US

Funding

Microbial triggers and molecular mechanisms of Th17 mediated airway inflammation-Resubmission-1R01HL125816 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KORALOV, SERGEI BORISOVICH · 2015 to 2019
$3.3M
Generation of a mouse expressing a photoactivatable Cre recombinaseR21AI124129 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KORALOV, SERGEI BORISOVICH, SCHWAB, SUSAN RUTH · 2016 to 2017
$466k
6 · The paper itself

Abstract

Cutaneous T-cell lymphoma (CTCL) is characterized by proliferation of malignant T cells in a chronic inflammatory environment. With disease progression, bacteria colonize the compromised skin barrier and half of CTCL patients die of infection rather than from direct organ involvement by the malignancy. Clinical data indicate that bacteria play a direct role in disease progression, but little is known about the mechanisms involved. Here, we demonstrate that bacterial isolates containing staphylococcal enterotoxin A (SEA) from the affected skin of CTCL patients, as well as recombinant SEA, stimulate activation of signal transducer and activator of transcription 3 (STAT3) and upregulation of interleukin (IL)-17 in immortalized and primary patient-derived malignant and nonmalignant T cells. Importantly, SEA induces STAT3 activation and IL-17 expression in malignant T cells when cocultured with nonmalignant T cells, indicating an indirect mode of action. In accordance, malignant T cells expressing an SEA-nonresponsive T-cell receptor variable region β chain are nonresponsive to SEA in monoculture but display strong STAT3 activation and IL-17 expression in cocultures with SEA-responsive nonmalignant T cells. The response is induced via IL-2 receptor common γ chain cytokines and a Janus kinase 3 (JAK3)-dependent pathway in malignant T cells, and blocked by tofacitinib, a clinical-grade JAK3 inhibitor. In conclusion, we demonstrate that SEA induces cell cross talk-dependent activation of STAT3 and expression of IL-17 in malignant T cells, suggesting a mechanism whereby SEA-producing bacteria promote activation of an established oncogenic pathway previously implicated in carcinogenesis.

Indexed as

Cell Line, TumorCoculture TechniquesEnterotoxinsFemaleGene Expression Regulation, NeoplasticHumansInterleukin-17Interleukin Receptor Common gamma SubunitLymphocyte ActivationMaleNeoplasm ProteinsPiperidinesPyrimidinesPyrrolesSezary SyndromeSTAT3 Transcription Factorenterotoxin A, StaphylococcalEnterotoxinsIL2RG protein, humanInterleukin-17Interleukin Receptor Common gamma SubunitNeoplasm ProteinsPiperidinesPyrimidinesPyrrolesSTAT3 protein, humanSTAT3 Transcription Factortofacitinib

Identifiers

PMID26738536
PMCPMC4786838
OpenAlexW2305188648

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.